Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 10—October 2008

Research

Prophylaxis after Exposure to Coxiella burnetii

Claire E. MoodieComments to Author , Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Figure 3

Decision tree for 100,000 pregnant women based on an assumption of an aerosolized, point source, overt attack with Coxiella burnetii (postexposure prophylaxis [PEP] with 160/800 mg trimethoprim-sulfamethoxazole 2×/d for duration of pregnancy, assuming 82% efficacy and 100% exposure.) PEP-related adverse events are not included in this figure. The “No PEP” segment of the tree contains the same branches and nodes as seen in the “With PEP” section, but uses different probabilities for certain varia

Figure 3. Decision tree for 100,000 pregnant women based on an assumption of an aerosolized, point source, overt attack with Coxiella burnetii (postexposure prophylaxis [PEP] with 160/800 mg trimethoprim-sulfamethoxazole 2×/d for duration of pregnancy, assuming 82% efficacy and 100% exposure.) PEP-related adverse events are not included in this figure. The “No PEP” segment of the tree contains the same branches and nodes as seen in the “With PEP” section, but uses different probabilities for certain variables. *The outcome of the unborn child is included in pregnant women illness estimates: low birth weight newborns were included in “Total Illness” estimates, and abortions/newborn deaths were included in all 3 outcome categories. QFS, Q fever fatigue syndrome.

Main Article

TOP